Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma

Quartuccio, Natale; Evangelista, Laura; Alongi, Pierpaolo; Caobelli, Federico; Altini, Corinna; Cistaro, Angelina; Lambertini, Alessandro; Schiorlin, Ilaria; Popescu, Cristina; Linguanti, Flavia; Laudicella, Riccardo; Scalorbi, Federica; Pierro, Giulia Di; Asabella, Artor Niccoli; Cuppari, Lea; Margotti, Simone; Lima, Giacomo Maria; Scalisi, Salvatore; Pacella, Sara; Kokomani, Aurora; Ciaccio, Alfonso; Sturiale, Letterio; Vento, Alessandro; Cardile, Davide; Baldari, Sergio; Panareo, Stefano; Fanti, Stefano; Rubini, Giuseppe; Schillaci, Orazio; Chiaravalloti, Agostino

doi:10.1097/mnm.0000000000001038

Cited by 11 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In five studies, either SUV max [ 29 , 41 , 43 ], SUV peak [ 29 ], wbSUL peak [ 43 ], presence of PET-positive lesions [ 41 , 43 , 44 , 45 ], MTV2.5, or TLG2.5 [ 29 ] showed a prognostic value. Two studies, including the largest study, did not find a significant prognostic value of any post-treatment PET parameter [ 36 , 42 ].…”

Section: Resultsmentioning

confidence: 99%

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

et al. 2021

View full text Add to dashboard Cite

Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed®, Cochrane, and Embase® were searched for papers addressing the prognostic value of any PET parameter at any treatment phase with any endpoint in patients with SCLC. Pooled hazard ratios (HRs) were calculated by a random effects model for the prognostic value of the baseline maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV). The qualitative analysis included 38 studies, of these, 19 studies were included in the meta-analyses. The pooled results showed that high baseline MTV was prognostic for overall survival (OS) (HR: 2.83 (95% confidence interval [CI]: 2.00–4.01) and progression-free survival (PFS) (HR: 3.11 (95% CI: 1.99–4.90)). The prognostic value of SUVmax was less pronounced (OS: HR: 1.50 (95% CI: 1.17–1.91); PFS: HR: 1.24 (95% CI: 0.94–1.63)). Baseline MTV is a strong prognosticator for OS and PFS in patients with SCLC. MTV has a prognostic value superior to those of other PET parameters, but whether MTV is superior to other prognosticators of tumor burden needs further investigation.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Molecular imaging investigations, especially F-FDG-PET/CT analysis, play an important role during early detection and follow-up in patients with both acute and chronic diseases [1,2]. In fact, molecular imaging techniques, such as single-photon emission computed tomography and PET, that use specific radiopharmaceuticals to image molecular interaction of biologic processes in vivo, are capable of delivering information about biomarkers expression and tissues biochemical characteristics [11,12].…”

Section: Discussionmentioning

confidence: 99%

“…The fluorine-18-fluorodeoxyglucose (F-FDG)-PET imaging analysis is widely used for the early diagnosis of pulmonary diseases [1]. Because activated inflammatory cells, such as malignant cells, predominantly metabolize glucose as a source of energy and increase expression of glucose transporters when activated, F-FDG-PET/CT can be successfully used to detect and monitor a variety of lung diseases, such as infections, several inflammatory conditions and neoplasms [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

18F-FDG-PET/CT analysis in hospitalized patients affected by pulmonary disease: The experience of the Nuclear Medicine Unit of “Policlinico Tor Vegata”

Urbano

Scimeca

Tavolozza

et al. 2021

Nuclear Medicine Communications

Self Cite

View full text Add to dashboard Cite

Objective The main aim of this study was to retrospectively evaluate the clinical data and outcomes of a cohort of 492 hospitalized patients who underwent fluorine-18-fluorodeoxyglucose (F-FDG)-PET/CT analysis at the nuclear medicine unit of ‘Policlinico Tor Vergata’ in Rome during the years 2017 and 2018 with particular emphasis for patients affected by pulmonary diseases. Methods Anamnestic data (age and gender), main pathologic conditions, results of F-FDG-PET/CT examination, appropriateness of the request, and medical records of 492 consecutive hospitalized patients who underwent F-FDG-PET/CT analysis (55.38 ± 3.78 years; range 33–81 years) from January 2017 to December 2018 were obtained. Results Considering all examinations, positive results were observed in 66.9% of cases whereas it was not possible to perform a diagnosis in 12.7% of cases (doubt results). About 20-fold increase in the percentage of doubt results was observed in F-FDG-PET/CT analysis with no appropriateness as compared to those with double appropriateness (both the request and clinical). Noteworthy, our data showed a 95% higher concordance between the positive results of the F-FDG-PET/CT examination and the histologic diagnosis. Conversely, the concordance between the analysis of the bronchoalveolar lavages and the PET analysis was very low. Conclusion Data here reported showed the high accuracy of the F-FDG-PET/CT performed in our department, mainly for pulmonary diseases, also highlighting the importance of continuously updating the selection criteria for patients who need PET examinations.

show abstract

“…More recently, new semiquantitative parameters, namely metabolic tumor volume (MTV) and total lesion glycolysis (TLG) rate, have been studied to evaluate the predictive and prognostic value of the metabolic tumor burden at baseline [18F]FDG PET/CT. Many of these studies have shown that new PET metabolic parameters are better in predicting prognosis in early and advanced NSCLC and SCLC patients than conventional PET parameters (SUVmax or SUVmean) [ 178 , 179 ].…”

Section: In Vivo Biomarkers For Immunotherapy: Molecular Imagingmentioning

confidence: 99%

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Liberini

Mariniello

Righi

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer-related death, and it is usually diagnosed in advanced stages (stage III or IV). Recently, the availability of targeted strategies and of immunotherapy with checkpoint inhibitors (ICI) has favorably changed patient prognosis. Treatment outcome is closely related to tumor biology and interaction with the tumor immune microenvironment (TME). While the response in molecular targeted therapies relies on the presence of specific genetic alterations in tumor cells, accurate ICI biomarkers of response are lacking, and clinical outcome likely depends on multiple factors that are both host and tumor-related. This paper is an overview of the ongoing research on predictive factors both from in vitro/ex vivo analysis (ranging from conventional pathology to molecular biology) and in vivo analysis, where molecular imaging is showing an exponential growth and use due to technological advancements and to the new bioinformatics approaches applied to image analyses that allow the recovery of specific features in specific tumor subclones.

show abstract

Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma

Cited by 11 publications

References 34 publications

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

18F-FDG-PET/CT analysis in hospitalized patients affected by pulmonary disease: The experience of the Nuclear Medicine Unit of “Policlinico Tor Vegata”

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Contact Info

Product

Resources

About